Recent clinical evidence, which suggests that anti-VEGF monoclonal antibody for treatment of metastatic cancer causes proteinuria and renal thrombotic microangiopathy, has dampened the enthusiasm for anti-angiogenic strategies for diabetic nephropathy. The gene discussed is VEGFA; the disease is metastatic malignant neoplasm.